Autor: |
Adachi E, Sedohara A, Arizono K, Takahashi K, Otani A, Kanno Y, Saito M, Koga M, Yotsuyanagi H |
Jazyk: |
angličtina |
Zdroj: |
Emerging infectious diseases [Emerg Infect Dis] 2024 Aug; Vol. 30 (8), pp. 1668-1671. |
DOI: |
10.3201/eid3008.240019 |
Abstrakt: |
A patient in Japan with HIV began antiretroviral therapy because of acute hepatitis B virus (HBV) 15 years ago, with low hepatitis B surface antibody, and experienced breakthrough HBV reactivation 4 months after switching from bictegravir/emtricitabine/tenofovir alafenamide to cabotegravir/rilpivirine. An immune escape mutation, E164V, was identified in the isolated HBV DNA. |
Databáze: |
MEDLINE |
Externí odkaz: |
|